216 related articles for article (PubMed ID: 7753690)
1. Trends in antimicrobial resistance among today's bacterial pathogens.
Thornsberry C
Pharmacotherapy; 1995; 15(1 Pt 2):3S-8S. PubMed ID: 7753690
[TBL] [Abstract][Full Text] [Related]
2. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Biedenbach DJ; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
Ko WC; Hsueh PR
J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
[TBL] [Abstract][Full Text] [Related]
13. Emergence and mechanisms of bacterial resistance in surgical infections.
Neu HC
Am J Surg; 1995 May; 169(5A Suppl):13S-20S. PubMed ID: 7755162
[TBL] [Abstract][Full Text] [Related]
14. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
[TBL] [Abstract][Full Text] [Related]
16. Community acquired bacterial infections and their antimicrobial susceptibility in Nairobi, Kenya.
Malonza IM; Omari MA; Bwayo JJ; Mwatha AK; Mutere AN; Murage EM; Ndinya-Achola JO
East Afr Med J; 1997 Mar; 74(3):166-70. PubMed ID: 9185414
[TBL] [Abstract][Full Text] [Related]
17. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
18. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
19. Redesigning beta-lactams to combat resistance: summary and conclusions.
Rossolini GM
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():30-3. PubMed ID: 17488374
[TBL] [Abstract][Full Text] [Related]
20. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
